• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (PubMed=16105816).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Unspecified (PubMed=20557307).
  

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9538136; DOI=10.3892/ijo.12.5.1103
Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H., Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.
Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Int. J. Oncol. 12:1103-1109(1998)

PubMed=14581340
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Clin. Cancer Res. 9:4705-4713(2003)

PubMed=15746151; DOI=10.1093/hmg/ddi092
Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I.
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hum. Mol. Genet. 14:997-1007(2005)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331
Nagai Y., Miyazawa H., Hu Q., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Cancer Res. 65:7276-7282(2005)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)

PubMed=22313637; DOI=10.4161/cbt.19238
Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Cancer Biol. Ther. 13:369-378(2012)

PubMed=22815900; DOI=10.1371/journal.pone.0041017; PMCID=PMC3398867
Tabara K., Kanda R., Sonoda K., Kubo T., Murakami Y., Kawahara A., Azuma K., Abe H., Kage M., Yoshinaga A., Tahira T., Hayashi K., Arao T., Nishio K., Rosell R., Kuwano M., Ono M.
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
PLoS ONE 7:E41017-E41017(2012)

PubMed=38639832; DOI=10.1007/s13577-024-01055-0; PMCID=PMC11194210
Kasai F., Fukushima M., Miyagi Y., Nakamura Y.
Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.
Hum. Cell 37:944-950(2024)